Ocular Hypertension

Ophthalmology·MeSH: Ocular Hypertension

Prevalence

47000.0 / 100K

Incidence

3000.0 / 100K/yr

10 drugs in development·5 companies·13 clinical trials

Drug Pipeline by Phase

Approved(8)

Drug	Company
bimatoprost	Amneal Pharmaceuticals, Inc. (AMRX)
brimonidine	Amneal Pharmaceuticals, Inc. (AMRX)
cosopt pf	AKORN INC (AKRX)
rescula	SUCAMPO PHARMACEUTICALS, INC. (SCMP)
rhopressa	AERIE PHARMACEUTICALS INC (AERI)
rocklatan	AERIE PHARMACEUTICALS INC (AERI)
timolol	Amneal Pharmaceuticals, Inc. (AMRX)
zioptan	AKORN INC (AKRX)

Phase 4(2)

Drug	Company
artificial tears	GH Research PLC (GHRS)
netarsudil ophthalmic solution 0.02%	GH Research PLC (GHRS)

BioSniper tracks 10 drugs in development for Ocular Hypertension across 5 companies.

There are 13 clinical trials targeting Ocular Hypertension tracked by BioSniper.

The estimated prevalence of Ocular Hypertension is approximately 47000.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.